Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Arbutus Biopharma Corp (NASDAQ:ABUS)

2.68
Delayed Data
As of Dec 02
 -0.025 / -0.93%
Today’s Change
2.45
Today|||52-Week Range
5.70
-39.89%
Year-to-Date
Foamix Completes Enrolment in Phase III Acne Drug Studies
Nov 30 / Zacks.com - Paid Partner Content
Intellipharmaceutics Submits NDA for Pain Treatment Rexista
Nov 28 / Zacks.com - Paid Partner Content
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
Nov 30 / Zacks.com - Paid Partner Content
New Strong Buy Stocks for November 28th
Nov 28 / Zacks.com - Paid Partner Content
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
Nov 30 / Zacks.com - Paid Partner Content
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.
Nov 25 / Zacks.com - Paid Partner Content
Epizyme Tazemetostat Gets Fast Track Designation in U.S.
Nov 29 / Zacks.com - Paid Partner Content
Merck (MRK) Announces 2.2% Increase in Quarterly Dividend
Nov 24 / Zacks.com - Paid Partner Content
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
Nov 29 / Zacks.com - Paid Partner Content
Juno's ROCKET Study on Clinical Hold Again, Shares Down
Nov 24 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close2.70
Today’s open2.65
Day’s range2.60 - 2.70
Volume173,464
Average volume (3 months)163,269
Market cap$146.7M
Dividend yield--
Data as of 3:59pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)+25.56%
Earnings growth (this year)-151.49%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+66.34%
P/E ratio--
Price/Sales8.13
Price/Book0.27

Competitors

 Today’s
change
Today’s
% change
VVUSVIVUS Inc-0.01-0.71%
NYMXNymox Pharmaceutical...+0.03+0.94%
GLYCGlycoMimetics Inc-0.13-2.11%
XENEXenon Pharmaceutical...-0.15-1.89%
Data as of 3:59pm ET, 12/02/2016

Financials

Next reporting dateMarch 15, 2017
EPS forecast (this quarter)-$0.37
Annual revenue (last year)$24.9M
Annual profit (last year)-$61.1M
Net profit margin-245.73%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark J. Murray
Chief Financial Officer &
Executive Vice President
Bruce G. Cousins
Corporate headquarters
Burnaby, British Columbia

Forecasts


Search for Jobs